GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecure SA (WAR:MOC) » Definitions » Short-Term Debt

Molecure (WAR:MOC) Short-Term Debt : zł0.00 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Molecure Short-Term Debt?

Molecure's Short-Term Debt for the quarter that ended in Dec. 2024 was zł0.00 Mil.


Molecure Short-Term Debt Historical Data

The historical data trend for Molecure's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecure Short-Term Debt Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Molecure Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Molecure Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Molecure Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Molecure's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecure Business Description

Traded in Other Exchanges
N/A
Address
Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.